US 11752138
Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
granted A61KA61K31/427A61K31/4439
Quick answer
US patent 11752138 (Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/427, A61K31/4439, A61K31/506